We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
FUJIREBIO

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
18 Mar 2021 - 21 Mar 2021
13 Apr 2021 - 16 Apr 2021

Early Differences in Cytokine Production Distinguish Severity of COVID-19

By LabMedica International staff writers
Posted on 27 Jan 2021
Print article
Image: The Bio-Plex Pro Human Cytokine Screening 48-plex panel (Photo courtesy of Bio-Rad Laboratories).
Image: The Bio-Plex Pro Human Cytokine Screening 48-plex panel (Photo courtesy of Bio-Rad Laboratories).
Most COVID-19 patients experience asymptomatic/mild symptoms, but some suffer critical symptoms requiring intensive care. It is important to determine how asymptomatic/mild patients react to SARS-CoV-2 infection and suppress virus spread.

It has been shown that several components of the immune response are dysregulated in COVID-19 patients with severe symptoms. Monocytes and macrophages were significantly dysregulated in severe patients. Dendritic cells and natural killer (NK) cells were depleted in COVID-19 patients compared to healthy controls, and it has been determined that those cells are dysregulated in the setting of SARS-CoV-2 infection.

A team of Clinical Virologists at the Kobe University Graduate School of Medicine (Kobe, Japan) analyzed cytokines induced by the innate immune response in 95 COVID-19 patients (median age, 50 years; 55% male) with different disease severities during their early phase of infection, less than 10 days after symptom onset or after an asymptomatic patient being notified of contact with a positive case. Of the patients, 16 were asymptomatic, 49 had mild disease, 11 had moderate disease, and 19 had severe disease.

The diagnosis of COVID-19 was determined by the detection of SARS-CoV-2 genome in a nasopharyngeal swab sample by polymerase chain reaction (PCR). Serum samples were subjected to the measurements of cytokines, chemokines, and growth factor (CCG) with the Bio-Plex Pro Human Cytokine Screening 48-plex panel (Bio-Rad Laboratories, Hercules, CA, USA) and the results were read using the Bio-Plex 200 system.

The team reported that IL-12 level was significantly higher in both the asymptomatic group and the mild group compared to the moderate and severe groups. Similarly, serum level of IL-2 was found to be significantly higher in the asymptomatic and mild COVID-19 patients compared with moderate and severe patients. Meanwhile, serum level of IL-18 was significantly higher in the symptomatic COVID-19 patients compared with asymptomatic patients and healthy controls. Similarly, the team found that IL-6 level increased with the severity level of COVID-19 in the acute phase. The investigators noted that IL-2 is also known as a growth factor for NK cells and has a synergistic effect with IL-18 to enhance the cytotoxicity and expansion of NK cells.

The authors concluded that their investigation was the first to show that during the acute phase of infection, significantly higher levels of IL-12 and IL-2 were induced in COVID-19 patients with asymptomatic and mild symptoms compared to those with moderate and severe symptoms, indicating the important roles of these two cytokines in the protection from severe COVID19. The study was published on January 7, 2021 in the Journal of Infectious Diseases.

Related Links:
Kobe University Graduate School of Medicine
Bio-Rad Laboratories


New
Gold Supplier
Tumor Marker Control
Tumor Marker Control
New
SARS-CoV-2/Influenza A & B/RSV Test
BIOSYNEX® AMPLIQUICK® SARS-COV-2 and Respiratory Triplex
PrimeStore MTM Kit
Sample Collection Kit
DNA/RNA Extraction Kit
Exiprep 96 Lite & Viral DNA/RNA Kit

Print article

Channels

Molecular Diagnostics

view channel
Image: Histopathologic image from a patient with Li Fraumeni syndrome showing accumulation of mutant TP53 in tumoral cells (Photo courtesy of Thierry Soussi, PhD).

Clinical Germline Testing Evaluated for Pediatric Cancer Patients

Pediatric cancer is rare, with fewer than 10,000 solid tumors diagnosed in children annually in the USA. Previous studies interrogating germline predisposition broadly across pediatric cancer types have... Read more

Industry

view channel
Illustration

Mindray and Tencent AI Lab to Jointly Develop AI Products for Blood Disease Screening and In Vitro Diagnosis

Shenzhen Mindray Biomedical Electronics Co., Ltd. (Shenzhen, China) has signed an AI cooperation framework agreement with Tencent AI Lab (Shenzhen, China) to jointly develop AI products for blood cell... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.